nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

12.01.2017 | Editorial Commentary

Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium

verfasst von: Orazio Schillaci, Nicoletta Urbano

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Excerpt

“It’s more important to know what sort of person has a disease than to know what sort of disease a person has,” stated Hippocrates of Kos (c. 460 – c. 370 BC). This sentence of the father of modern medicine, which is based on observation of clinical signs and rational conclusions, is truly actual and it can be considered the manifesto of personalized (or precision) medicine (PM). According to the National Heart, Lung, and Blood Institute, PM is the use of diagnostic and screening methods to better manage the individual patient’s disease or predisposition toward a disease; it will enable risk assessment, diagnosis, prevention, and therapy specifically tailored to the unique characteristics of the individual, thus enhancing the quality of life and public health. …

Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–5.CrossRefPubMedPubMedCentral

Sobradillo P, Pozo F, Agustí A. P4 medicine: the future around the corner. Arch Bronconeumol. 2011;47:35–40.CrossRefPubMed

Flores M, Glusman G, Brogaard K, Price ND, Hood L. P4 medicine: how systems medicine will transform the healthcare sector and society. Per Med. 2013;10:565–76.CrossRefPubMedPubMedCentral

Jung KH, Lee KH. Molecular imaging in the era of personalized medicine. J Pathol Transl Med. 2015;49:5–12.CrossRefPubMedPubMedCentral

Kircher MF, Hricak H, Larson SM. Molecular imaging for personalized cancer care. Mol Oncol. 2012;6:182–95.CrossRefPubMed

European Society of Radiology (ESR). Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Imaging. 2015;6:141–55.CrossRef

Kuo MD, Jamshidi N. Behind the numbers: Decoding molecular phenotypes with radiogenomics--guiding principles and technical considerations. Radiology. 2014;270:320–5.CrossRefPubMed

Lee JD, Yun M, Lee JM, Choi Y, Kim JS, Kim SJ, et al. Analysis of gene expression profiles of hepatocellular carcinomasd with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging. 2004;31:1621–30.

Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Bernd L, Haberkorn U, Ewerbeck V, et al. 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med. 2004;45:1528–35.PubMed

10.

Strauss LG, Koczan D, Klippel S, Pan L, Cheng C, Willis S, et al. Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med. 2008;49:1238–44.CrossRefPubMed

11.

Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Pan L, Hohenberger P. Correlation of dynamic PET and gene array data in patients with gastrointestinal stromal tumors. Sci World J. 2012;2012:721313.CrossRef

12.

Rink L, Ochs MF, Zhou Y, von Mehren M, Godwin AK. ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor. PLoS One. 2013;8:e54477.CrossRefPubMedPubMedCentral

13.

Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, et al. F-18-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: Microarray and immunohistochemical analysis. J Nucl Med. 2010;51:543–50.CrossRefPubMedPubMedCentral

14.

Nair VS, Gevaert O, Davidzon G, Napel S, Graves EE, Hoang CD, et al. Prognostic PET F-18-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res. 2012;72:3725–34.CrossRefPubMedPubMedCentral

15.

Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J, et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res. 2008;14:7397–404.

16.

Gevaert O, Xu J, Hoang CD, Leung AN, Xu Y, Quon A, et al. Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. Radiology. 2012;264:387–96.CrossRefPubMedPubMedCentral

17.

Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.CrossRefPubMed

18.

Kawada K, Toda K, Nakamoto Y, Iwamoto M, Hatano E, Chen F, et al. K, Date H, Uemoto S, Sakai Y. Relationship between 18F-FDG PET/CT scans and KRAS mutations in metastatic colorectal cancer. J Nucl Med. 2015;56:1322–7.CrossRefPubMed

19.

Kawada K, Nakamoto Y, Kawada M, Hida K, Matsumoto T, Murakami T, et al. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res. 2012;18:1696–703.CrossRefPubMed

20.

Lee JH, Kang J, Baik SH, Lee KY, Lim BJ, Jeon TJ, et al. Relationship between 18F-Fluorodeoxyglucose uptake and V-Ki-Ras2 Kirsten rat sarcoma viral oncogene homolog mutation in colorectal cancer patients: variability depending on C-reactive protein level. Medicine (Baltimore). 2016;95:e2236. doi:10.1097/MD.0000000000002236.CrossRef

21.

Colen R, Foster I, Gatenby R, Giger ME, Gillies R, Gutman D, et al. NCI workshop report: clinical and computational requirements for correlating imaging phenotypes with genomics signatures. Transl Oncol. 2014;24(7):556–69.CrossRef

22.

Hatt M, Tixier F, Pierce L, Kinahan PE, Cheze Le Rest C, Visvikis D. Characterization of PET/CT images using texture analysis: the past, the present…any future? Eur J Nucl Med Mol Imaging. 2017;44:151–65.CrossRefPubMed

23.

Chen SW, Shen WC, Lin YC, Chen RY, Hsieh TC, Yen KY, et al. Correlation of pretreatment (18)F-FDG PET tumor textural features with gene expression in pharyngeal cancer and implications for radiotherapy-based treatment outcomes. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3580-5.PubMedCentral

24.

Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563–77.CrossRefPubMed

25.

Hatt M, Tixier F, Cheze Le Rest C. Radiomics in PET/CT: more than meets the eye? J Nucl Med. 2016. doi:10.2967/jnumed.116.184655.

Titel: Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium
verfasst von: Orazio Schillaci
Nicoletta Urbano
Publikationsdatum: 12.01.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3616-5

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor

Diffuse 18F-FDG accumulation in the subarachnoid space detected by PET/CT in a patient with subarachnoid hemorrhage and hyperglycemia

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients

Radionuclide therapy of malignant bone lesions

Michael Schuenke, Erik Schulte, Udo Schumacher (Editors): Atlas of anatomy: head, neck, and neuroanatomy

Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC